Enter Symbol:
NUCRYST PHARMACEUTICALS CORP
Front Runners
NCST @ Yahoo Finance NCST Option @ Yahoo Finance
Stock Details
Current Price	High	Value Change	Percent Change	Dividend	Previous Close
$ 1.77	$ 1.77	$ 0.02	1.03%	3.20	$ 1.75
Opening Price	Low	Volume	Market Cap	Average Volume	P/E
$ 1.77	$ 1.77	5,633	32.44M	61,108.55	177.00
Pivot Table
R2 R1 Pivot S1 S2 1.77 1.77 1.77 1.77 1.77

NUCRYST Pharmaceuticals Corp. develops, manufactures, and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. It produces nanocrystalline silver as a coating for wound dressing products under the trademark ‘SILCRYST' and as a powder for use as an active pharmaceutical ingredient, which is known as NPI 32101. The company licenses its technology to Smith & Nephew plc, which markets, distributes, and sells products using the company's SILCRYST coatings. These products include Acticoat 3/Acticoat Burn Dressings; Acticoat 7 Dressings; Acticoat Absorbent Dressings; and Acticoat and Moisture Control Dressings. NUCRYST Pharmaceuticals' products are used by hospitals, clinics, burn centers, doctors, offices, home healthcare agencies, and nursing homes for the treatment of various wound types, such as chronic wounds, serious burns, and traumatic and surgical wounds. It also focuses on developing pharmaceutical products containing its NPI 32101 silver to extend the company's nanocrystalline silver technology to the treatment of gastrointestinal conditions. In addition, the company develops a topical cream containing NPI 32101 as a barrier to infection; and involves in the research of potential pharmaceutical products containing NPI 32101 for use in the treatment of gastrointestinal disorders. NUCRYST Pharmaceuticals was founded in 1997 and is headquartered in Wakefield, Massachusetts. NUCRYST Pharmaceuticals Corp. is a subsidiary of The Westaim Corporation.